-
Novartis' pill, PTK-787, hit the same molecular target as Genentech's blockbuster, and was seen as a potentially fearsome competitor.
FORBES: Two Wins For Biotech
-
It does hit a specific molecular target in the cell called VEGF.
FORBES: Real Cancer Drug Breakthrough Is Astronomical Prices
-
But he admits that the exact molecular target is still unknown.
FORBES: Magazine Article
-
One possibility is that the amyloid theory is right, but that the Eli Lilly drug is flawed and did not hit the proper molecular target, and ended up merely causing toxicity.
FORBES: Eli Lilly Alzheimer's Disease Failure Bolsters Amyloid Theory Skeptics
-
High-throughput screening uses robots to test the actions of thousands of compounds against a molecular disease target (itself identified by genomics).
FORBES: A hail of silver bullets
-
Astra actually launched one of the first cancer drugs to target a molecular defect in tumors, the lung cancer pill, Iressa.
FORBES: AstraZeneca's Victory Highlights Difficulty Of Cancer Drug Development
-
When Schleifer, a 50-year-old neurologist, cofounded Regeneron with George Yancopoulos , a molecular immunologist, the main target was Lou Gehrig's disease.
FORBES: Hunger Pangs
-
Huang is now turning his focus beyond gamers to a host of new customers that will need number-crunching power: oil companies doing deep-sea seismic analysis, Wall Street banks modeling portfolio risk and biologists visualizing molecular structures to find drug target sites.
FORBES: Magazine Article
-
Typically, these are motivated by a conspicuous success, a development program that was driven by the strength of beautiful molecular data, and the canonical example these days is PCSK9, a target which seems to feature an almost unprecedented alignment of human genetics, biomarker, and animal model data.
FORBES: Strategy: Why Big Pharmas Do What They Do -- And How Silicon Valley Might Help Them Think Differently
-
At issue is the way that Medicare reimburses everyone from the big laboratory companies such as the Laboratory Corp of America (LH:NYSE) and Quest Diagnostics Inc. (DGX:NYSE), to the molecular diagnostic labs inside academic hospitals, and especially smaller firms that make proprietary tests used by doctors to more effectively target treatments to patients with conditions like cancer.
FORBES: Medicare Has Stopped Paying Bills For Medical Diagnostic Tests. Patients Will Feel The Effects